Real-World Insights Challenge Weight Regain Concerns with GLP-1 Drugs

Recent findings from a real-world study challenge concerns about rapid weight regain after discontinuing GLP-1 drugs like Wegovy, offering hope for patients managing obesity. Data from 135,000 patients collected by nference suggests stability or further weight loss rather than immediate regain, contrary to fears based on clinical trials.

The research, conducted in U.S. academic clinics, found that many patients maintained or lost more weight even 18 months after stopping drugs like semaglutide and tirzepatide. While the study awaits peer review, it highlights the need for a sustained lifestyle change alongside medication for effective weight management.

Obesity specialists note that understanding who can safely discontinue or require intermittent GLP-1 drug treatment could revolutionize obesity management. Despite limitations in accounting for all lifestyle factors, the study suggests a potential for long-term benefits and underscores the significance of behavior change in achieving lasting outcomes.